- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Strides Pharma Science biologics arm gets EMA nod for osteoporosis drug Kauliv
Kauliv is a biosimilar to Forsteo (innovator product), indicated for both men and postmenopausal women with osteoporosis who are at high risk for having broken bones or fractures.
Bengaluru: Stelis Biopharma Limited, the biologics arm of Strides Pharma Science Limited, has received a positive recommendation from the European Medicines Agency (EMA) for granting market authorization for the osteoporosis drug Kauliv.
"Stelis Biopharma Limited, the biologics arm of Strides Pharma Science Limited, announced that its product division Biolexis has a major success with its first biosimilar product Kauliv receiving a positive recommendation from European Medicines Agency (EMA) for granting of market authorization," the company stated.
Kauliv is a recombinant human teriparatide injection intended for the treatment of osteoporosis. The Company informed that EMA's Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion, recommending granting marketing authorization for Kauliv on November 11, 2022.
Kauliv is a biosimilar to Forsteo (innovator product), indicated for both men and postmenopausal women with osteoporosis who are at high risk for having broken bones or fractures. The product is developed on a recombinant Escherichia coli host platform, similar to the innovator. Kauliv provides reusable and disposable pen device options to cater to the global market demand.
Forsteo (innovator product) is currently the market leader among the treatment options of bisphosphonates and Selective Estrogen Receptor Modulators (SERMs) and remains a gold standard drug for the treatment of osteoporosis with >$800 million global sales in a total market size of >$1.5 billion.
Kauliv will be available as a 20 μg/80 μl solution for injection. At the molecular level, teriparatide binds to the human parathyroid hormone receptor with a similar affinity as the human parathyroid hormone and effect a similar molecular signaling mechanism to act on bone metabolism.
For the European markets, Kauliv will utilize a 'CE' marked reusable pen device developed based on the clinically proven Autopen platform by Owen Mumford Limited (a United Kingdom-based medical device design and manufacture company).
Stelis will manufacture this product at its USFDA and EU authority-approved facilities in Bangalore, India, and will scale the opportunity globally through a B2B model. The Company has already licensed Kauliv across 20 countries, and the commercialization of the product will generate incremental revenues for Company starting FY24 after country-specific registrations are completed.
Read also: Strides Pharma Kenya based arm bags WHO certification to produce antimalarial drug
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751